Results 51 to 60 of about 14,898 (265)

Vigabatrin and Epilepsy: Lessons Learned [PDF]

Epilepsia, 2007
Summary:  Purpose: The risk factors for visual field loss attributable to vigabatrin (VAVFL) are equivocal. This multinational, prospective, observational study aimed to clarify the principal/major factors for VAVFL. Methods: Interim analysis of three groups with refractory partial epilepsy, stratified by age (8–12 years; >12 years) and exposure to
PERUCCA, EMILIO, 1.3. Wild, J. M. , Ahn, H. , Baulac, M. , Bursztyn, J. , C.h.i.r.o.n. C., Gandolfo, E., Safran, A. B., Schiefer, U.   +8 more
openaire   +4 more sources

Medication‐resistant epilepsy is associated with a unique gut microbiota signature

Epilepsia, EarlyView.
Abstract Objective Dysfunction of the microbiota–gut–brain axis is emerging as a new pathogenic mechanism in epilepsy, potentially impacting on medication response and disease outcome. We investigated the composition of the gut microbiota in a cohort of medication‐resistant (MR) and medication‐sensitive (MS) pediatric patients with epilepsy.
Antonella Riva, Eray Sahin, Greta Volpedo, Noemi Teresa Catania, Isabel Venara, Valentina Biagioli, Ganna Balagura, Elisabetta Amadori, Carmen De Caro, Emanuele Cerulli Irelli, Carlo Di Bonaventura, Federico Zara, Osman Ugur Sezerman, Emilio Russo, Pasquale Striano   +14 more
wiley   +1 more source

Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review. [PDF]

, 2016
Antiepileptic drugs (AEDs) have many benefits but also many side effects, including aggression, agitation, and irritability, in some patients with epilepsy.
Alan B. Ettinger, Albert P. Aldenkamp, Bernhard J. Steinhoff, Besag, Biton, Brodkin, Brown, Carmichael, Chiaretti, Coccaro, Cánovas Martínez, David R. Sibley, Delgado-Escueta, Devinsky, Dolton, D’Souza, Edwards, Elliott, Ettinger, Feindel, Flor-Henry, Frank Besag, Friedman, Gabriella Gobbi, Gedye, Gobbi, Gollan, Hemming, Huband, Jan, Kang, Klüver, Krishnamoorthy, Kugaya, Lander, Landolt, Lee, LoPresti, Loup, Maletzky, Maletzky, Marco Mula, Martin J. Brodie, Mpakopoulou, Mula, Olsen, Pandya, Ratner, Raucci, Robinson, Ruuskanen, Schmitz, Seidenwurm, Shehata, Silver, Stefano Comai, Steinhoff, Szczurowska, Turski, Van Paesschen, Wieshmann   +60 more
core   +3 more sources

Expanding the therapeutic role of highly purified cannabidiol in monogenic epilepsies: A multicenter real‐world study

Epilepsia, EarlyView.
Abstract Objective This real‐world, retrospective, multicenter study aims to investigate the effectiveness of highly purified cannabidiol (CBD) in a large cohort of patients with epilepsy of genetic etiology due to an identified monogenic cause. Additionally, we examine the potential relationship between specific genetic subgroups and treatment ...
Emanuele Cerulli Irelli, Adolfo Mazzeo, Roberto H. Caraballo, Marco Perulli, Patrick B. Moloney, Javier Peña‐Ceballos, Marica Rubino, Katarzyna M. Mieszczanek, Andrea Santangelo, Laura Licchetta, Valentina De Giorgis, Gabriela Reyes Valenzuela, Susanna Casellato, Elisabetta Cesaroni, Francesca F. Operto, Jana Domínguez‐Carral, Alia Ramírez‐Camacho, Alessandro Ferretti, Giuseppe Santangelo, Angel Aledo‐Serrano, Andrea Rüegger, Maria M. Mancardi, Giulia Prato, Antonella Riva, Luca Bergonzini, Duccio M. Cordelli, Paolo Bonanni, Francesca Bisulli, Giancarlo Di Gennaro, Sara Matricardi, Pasquale Striano, Norman Delanty, Carla Marini, Domenica Battaglia, Carlo Di Bonaventura, Georgia Ramantani, Elena Gardella, GENE‐CBD Study Group, Alessandro Orsini, Antonietta Coppola, Alessandra Morano, Nicola Simeone, Claudia Cuccurullo, Massimo Scacciati, Alice Bonuccelli, Maddalena Bianchetti, Alberto Verrotti, Marta Piccioli, Massimiliano Celario, Elena Tartara, Giulia Balletto, Chiara Bagliani, Beatriz Gonzalez Giraldez, Pasquale Parisi, Carmen Salluce, Emanuele Bartolini, Maria Del Carmen Fons‐Estupiña, Federico Ramos, Alberto Danieli, Alessandra Rossi, Elisabetta Pantaloni, Ana Laura Fernandez‐Perrone, Giorgio Magli, Ilaria Onida, Giulia Bruschi, Lorenzo Muccioli, Tomasz S. Mieszczanek, Trine Hammer, Francesca Furia   +68 more
wiley   +1 more source

Clinical pharmacology of vigabatrin. [PDF]

British Journal of Clinical Pharmacology, 1989
1. Upon oral administration vigabatrin is rapidly absorbed. Plasma elimination half‐life ranges between 5 and 7 h in normal volunteers. Vigabatrin is eliminated primarily via the kidneys with about 65% of the administered dose found unchanged in the urine within 24 h. Kinetics are dose‐linear within the range of usual therapeutic doses. 2.
openaire   +3 more sources

Retinal structure and function in vigabatrin‐treated adult patients with refractory complex partial seizures

Epilepsia, 2016
Evaluate visual‐field and retinal‐structure changes following adjunctive vigabatrin treatment in vigabatrin‐naive adults with refractory complex partial seizures (rCPS).
R. Sergott, Chris A. Johnson, K. Laxer, R. Wechsler, K. Cherny, J. Whittle, G. Feng, Deborah Lee, J. Isojarvi   +8 more
semanticscholar   +1 more source

Prevalence, clinical characteristics, and risk factors for psychosis in people with epilepsy: A multicenter retrospective cohort study

Epilepsia, EarlyView.
Abstract Objective We aimed to assess the prevalence, clinical characteristics, and risk factors for psychosis in a cohort of people with epilepsy in West China. Methods We used retrospective information from databases of three tertiary epilepsy centers, which included follow‐up records from 2006 onward.
Sisi Shen, Hanlin Sun, Zaiquan Dong, Tong Yi, Josemir W. Sander, Dong Zhou, Jinmei Li   +6 more
wiley   +1 more source

Intravitreal triamcinolone acetonide as an adjunct in the treatment of severe ocular toxoplasmosis [PDF]

, 2006
Universidade Federal de São Paulo, Vis Inst, São Paulo, BrazilUniversidade Federal de São Paulo, Vis Inst, São Paulo, BrazilWeb of ...
C Muccioli, F B Aggio, JB Jonas, JM Benitez Del Castillo Sanchez, K Kishore, R Belfort, RB Nussenblatt   +6 more
core   +1 more source

The human photosensitive epilepsy model for clinical proof‐of‐principle trials of novel antiseizure medications: 2. Analysis of drug trials and predictive value of the model

Epilepsia, EarlyView.
Abstract Clinical development of novel antiseizure medications (ASMs) would benefit from an early proof of principle (POP) model. The photosensitivity model, which uses the photoparoxysmal electroencephalographic response (PPR) as a surrogate of seizures, is currently the only human model that allows POP trials of investigational compounds after a ...
Wolfgang Löscher, Dorothée Kasteleijn‐Nolst Trenité   +1 more
wiley   +1 more source

Use of ACTH and prednisolone in infantile spasms: Experience from a developing country [PDF]

, 2005
SummaryBackground: Adrenocorticotrophic hormone (ACTH) and prednisone are both used to treat infantile spasms (IS) in West syndrome. In many countries, ACTH is expensive and difficult to obtain whereas, prednisone or prednisolone are cheap, given orally ...
Appleton, Baram, Baram, Bobele, Commission on Antiepileptic Drugs of ILAE, Donat, Glaze, Gomez, Haine, Hancock, Hancock, Harding GFA, Hrachovy, Hrachovy, Hrachovy, Hwang, Jai Krishin, Kalra, Lombroso, Mackay, Matloob Azam, Nasera Bhatti, Salonga, Sher, Sorel, Vigevano, Wong   +26 more
core   +1 more source